Carlos Dzik, MD

Articles by Carlos Dzik, MD

Expanding Androgen- and Androgen Receptor Signaling–Directed Therapies for Castration-Resistant Prostate Cancer

ByDiogo A. Bastos, MD,Carlos Dzik, MD,Dana Rathkopf, MD,Howard I. Scher, MD

Published: August 15th 2014 | Updated: November 11th 2020

This article reviews the most recent advances in androgen receptor-directed therapies for castration-resistant prostate cancer, and new agents under development.

Latest Updated Articles

Expanding Androgen- and Androgen Receptor Signaling–Directed Therapies for Castration-Resistant Prostate Cancer
Published: August 15th 2014 | Updated: November 11th 2020

Carlos Dzik, MD

Articles by Carlos Dzik, MD

Expanding Androgen- and Androgen Receptor Signaling–Directed Therapies for Castration-Resistant Prostate Cancer

Latest Updated Articles

Trending on CancerNetwork

FDA Grants Accelerated Approval to Zongertinib in HER2+ NSCLC

Olaparib Combo Improves PFS/OS in BRCA+ or ATM+ Metastatic CRPC

Enzalutamide/Radium-223 Extends Survival in mCRPC

Relacorilant Plus Nab-Paclitaxel Significantly Improves Survival in PROC

Reducing Disease Risk on National Cancer Prevention Month